Arch Pharmalabs Unlisted Share

The Arch pharmalabs  company operates in two main areas: Products and Services. The Products segment focuses on manufacturing and selling APIs and Intermediates to both innovator and generic pharma companies in domestic and international, including regulated, markets. Over time, the company has expanded its offerings to include CRAMS (Contract Research and Manufacturing Services), which presents significant growth opportunities.

They presently have 8 manufacturing facilities across India. All these 8 manufacturing facilities are multipurpose with reactor capacities of around 1200 K.

Product Portfolio

API Manufacturing

Intermediate Manufacturing

 Contract Services

CRAMS

• Arch Pharmalabs expanded into Contract Research and Manufacturing Services (CRAMS).

• Provides full services from process development to commercial manufacturing (US/EU compliant).

• Utilizes proprietary bio-catalytic and enzymatic technologies for efficient production.

• Focuses on NCE synthesis, complex product manufacturing, and on-patent API production.

• Partners with innovator firms to secure long-term contracts and deliver customized solutions.

• Aims to be a high-value global player through strategic acquisitions and specialized services.

Management 

Industry Overview

The Indian pharmaceutical industry, valued at ₹4.15 lakh crore in 2024, is growing at 11-12% CAGR and projected to reach ₹6.64-7.47 lakh crore by 2028. A global leader in APIs, CRAMS, and generics, it’s expanding in emerging markets, driven by AI, biotech, and the PLI scheme. However, it faces challenges like regulatory compliance, cost pressures, and IP concerns.

SWOT Analysis

Financial Highlights

Peer Comparison

Arch Pharmalabs Annual Report 2022-23

Arch Pharmalabs Annual Report 2021-22

Arch Pharmalabs Annual Report 2020-21